Iradimed Total Revenue vs Net Income From Continuing Ops Analysis

IRMD Stock

USD 53.93 0.35 0.65%

Iradimed financial indicator trend analysis is infinitely more than just investigating Iradimed recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iradimed is a good investment. Please check the relationship between Iradimed Total Revenue and its Net Income From Continuing Ops accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Total Revenue vs Net Income From Continuing Ops

Total Revenue vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iradimed Total Revenue account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Iradimed's Total Revenue and Net Income From Continuing Ops is 0.82. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Iradimed Co, assuming nothing else is changed. The correlation between historical values of Iradimed's Total Revenue and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Iradimed Co are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Total Revenue i.e., Iradimed's Total Revenue and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Revenue

Total revenue comprises all receipts Iradimed generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Net Income From Continuing Ops

Most indicators from Iradimed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iradimed current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At present, Iradimed's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 51.09, whereas Selling General Administrative is forecasted to decline to about 9.3 M.

	2021	2022	2023	2024 (projected)
Gross Profit	32.0M	41.3M	50.2M	27.1M
Total Revenue	41.8M	53.3M	65.6M	35.1M

Gross Profit Total Revenue

Iradimed fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.59	0.55	0.68	1.0	0.78	0.68	0.94	-0.97	0.99	0.77	0.98	0.76	0.51	0.42	0.98	0.78	0.94	0.87	-0.13	0.91	0.63	0.65	0.95	0.79	0.7
Short Long Term Debt Total	0.59		0.07	0.19	0.62	0.71	0.24	0.46	-0.53	0.56	0.42	0.54	0.29	0.16	0.39	0.66	0.28	0.77	0.64	0.68	0.52	0.24	0.31	0.71	0.3	0.18
Other Current Liab	0.55	0.07		0.97	0.51	0.26	0.95	0.47	-0.57	0.49	0.58	0.47	0.93	0.13	-0.14	0.44	0.81	0.56	0.56	-0.43	0.47	0.95	0.22	0.52	0.92	0.96
Total Current Liabilities	0.68	0.19	0.97		0.65	0.42	0.95	0.64	-0.7	0.64	0.7	0.6	0.97	0.29	-0.05	0.59	0.9	0.67	0.69	-0.37	0.58	0.98	0.3	0.63	0.98	0.99
Total Stockholder Equity	1.0	0.62	0.51	0.65		0.78	0.65	0.93	-0.98	0.99	0.75	0.99	0.73	0.53	0.45	0.99	0.76	0.94	0.87	-0.1	0.9	0.6	0.67	0.96	0.76	0.67
Other Liab	0.78	0.71	0.26	0.42	0.78		0.51	0.73	-0.75	0.81	0.44	0.75	0.57	0.24	0.62	0.8	0.49	0.74	0.76	0.16	0.89	0.43	0.49	0.67	0.58	0.43
Property Plant And Equipment Net	0.68	0.24	0.95	0.95	0.65	0.51		0.57	-0.7	0.63	0.57	0.61	0.98	0.09	0.1	0.6	0.8	0.68	0.69	-0.34	0.67	0.95	0.4	0.63	0.97	0.96
Current Deferred Revenue	0.94	0.46	0.47	0.64	0.93	0.73	0.57		-0.92	0.96	0.74	0.93	0.68	0.68	0.37	0.91	0.79	0.8	0.79	-0.22	0.82	0.58	0.59	0.83	0.73	0.65
Net Debt	-0.97	-0.53	-0.57	-0.7	-0.98	-0.75	-0.7	-0.92		-0.97	-0.68	-0.99	-0.77	-0.53	-0.44	-0.98	-0.79	-0.88	-0.88	0.23	-0.89	-0.63	-0.72	-0.92	-0.8	-0.72
Retained Earnings	0.99	0.56	0.49	0.64	0.99	0.81	0.63	0.96	-0.97		0.72	0.99	0.72	0.54	0.46	0.98	0.75	0.88	0.86	-0.17	0.92	0.58	0.68	0.9	0.76	0.65
Accounts Payable	0.77	0.42	0.58	0.7	0.75	0.44	0.57	0.74	-0.68	0.72		0.68	0.67	0.64	0.0	0.68	0.86	0.78	0.71	-0.07	0.57	0.67	0.12	0.76	0.7	0.71
Cash	0.98	0.54	0.47	0.6	0.99	0.75	0.61	0.93	-0.99	0.99	0.68		0.69	0.54	0.48	0.99	0.72	0.87	0.84	-0.21	0.91	0.53	0.74	0.92	0.73	0.63
Non Current Assets Total	0.76	0.29	0.93	0.97	0.73	0.57	0.98	0.68	-0.77	0.72	0.67	0.69		0.27	0.13	0.68	0.89	0.74	0.75	-0.34	0.72	0.96	0.39	0.69	1.0	0.98
Non Currrent Assets Other	0.51	0.16	0.13	0.29	0.53	0.24	0.09	0.68	-0.53	0.54	0.64	0.54	0.27		0.16	0.51	0.65	0.39	0.41	-0.22	0.34	0.21	0.1	0.47	0.32	0.34
Other Assets	0.42	0.39	-0.14	-0.05	0.45	0.62	0.1	0.37	-0.44	0.46	0.0	0.48	0.13	0.16		0.49	0.04	0.35	0.35	0.04	0.59	-0.06	0.56	0.39	0.12	0.02
Cash And Short Term Investments	0.98	0.66	0.44	0.59	0.99	0.8	0.6	0.91	-0.98	0.98	0.68	0.99	0.68	0.51	0.49		0.71	0.92	0.87	-0.07	0.89	0.54	0.71	0.95	0.71	0.61
Net Receivables	0.78	0.28	0.81	0.9	0.76	0.49	0.8	0.79	-0.79	0.75	0.86	0.72	0.89	0.65	0.04	0.71		0.73	0.76	-0.34	0.65	0.85	0.23	0.73	0.91	0.92
Common Stock Total Equity	0.94	0.77	0.56	0.67	0.94	0.74	0.68	0.8	-0.88	0.88	0.78	0.87	0.74	0.39	0.35	0.92	0.73		0.86	0.15	0.8	0.67	0.54	0.98	0.75	0.68
Common Stock Shares Outstanding	0.87	0.64	0.56	0.69	0.87	0.76	0.69	0.79	-0.88	0.86	0.71	0.84	0.75	0.41	0.35	0.87	0.76	0.86		0.01	0.76	0.68	0.52	0.85	0.78	0.69
Short Term Investments	-0.13	0.68	-0.43	-0.37	-0.1	0.16	-0.34	-0.22	0.23	-0.17	-0.07	-0.21	-0.34	-0.22	0.04	-0.07	-0.34	0.15	0.01		-0.19	-0.25	-0.24	0.04	-0.36	-0.41
Non Current Liabilities Total	0.91	0.52	0.47	0.58	0.9	0.89	0.67	0.82	-0.89	0.92	0.57	0.91	0.72	0.34	0.59	0.89	0.65	0.8	0.76	-0.19		0.53	0.63	0.8	0.74	0.62
Inventory	0.63	0.24	0.95	0.98	0.6	0.43	0.95	0.58	-0.63	0.58	0.67	0.53	0.96	0.21	-0.06	0.54	0.85	0.67	0.68	-0.25	0.53		0.25	0.59	0.95	0.97
Other Current Assets	0.65	0.31	0.22	0.3	0.67	0.49	0.4	0.59	-0.72	0.68	0.12	0.74	0.39	0.1	0.56	0.71	0.23	0.54	0.52	-0.24	0.63	0.25		0.61	0.41	0.31
Other Stockholder Equity	0.95	0.71	0.52	0.63	0.96	0.67	0.63	0.83	-0.92	0.9	0.76	0.92	0.69	0.47	0.39	0.95	0.73	0.98	0.85	0.04	0.8	0.59	0.61		0.72	0.65
Total Liab	0.79	0.3	0.92	0.98	0.76	0.58	0.97	0.73	-0.8	0.76	0.7	0.73	1.0	0.32	0.12	0.71	0.91	0.75	0.78	-0.36	0.74	0.95	0.41	0.72		0.98
Property Plant And Equipment Gross	0.7	0.18	0.96	0.99	0.67	0.43	0.96	0.65	-0.72	0.65	0.71	0.63	0.98	0.34	0.02	0.61	0.92	0.68	0.69	-0.41	0.62	0.97	0.31	0.65	0.98

Click cells to compare fundamentals

Iradimed Account Relationship Matchups

Iradimed fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	66.7M	71.1M	82.9M	85.5M	92.2M	54.5M
Other Current Liab	3.0M	2.0M	3.1M	3.0M	10.7M	11.2M
Total Current Liabilities	5.9M	4.9M	6.8M	8.6M	16.3M	17.1M
Total Stockholder Equity	55.5M	61.4M	72.2M	73.7M	71.4M	46.1M
Other Liab	2.6M	2.3M	1.7M	1.4M	1.6M	1.4M
Property Plant And Equipment Net	5.0M	4.8M	4.6M	2.4M	11.3M	11.9M
Current Deferred Revenue	1.7M	1.9M	2.6M	3.4M	2.6M	1.7M
Net Debt	(40.5M)	(47.4M)	(59.5M)	(55.8M)	(47.7M)	(45.3M)
Retained Earnings	36.3M	37.7M	47.0M	47.3M	43.3M	27.5M
Accounts Payable	993.7K	657.1K	782.9K	1.8M	1.9M	1.0M
Cash	43.5M	50.1M	62.0M	58.0M	49.8M	33.0M
Non Current Assets Total	7.8M	7.3M	6.6M	7.3M	16.2M	17.0M
Non Currrent Assets Other	232.0K	262.0K	201.3K	2.2M	181.4K	336.3K
Other Assets	1.9M	6.4M	966.4K	1.3M	1.0	0.95
Cash And Short Term Investments	46.3M	52.0M	62.5M	58.0M	49.8M	37.0M
Net Receivables	7.3M	4.6M	5.1M	13.3M	12.2M	12.8M
Common Stock Total Equity	1.2K	1.2K	1.3K	1.3K	1.4K	1.2K
Common Stock Shares Outstanding	12.3M	12.4M	12.6M	12.6M	12.7M	13.0M
Short Term Investments	8.1M	6.3M	2.8M	1.9M	501.9K	0.0
Liabilities And Stockholders Equity	66.7M	71.1M	82.9M	85.5M	92.2M	54.5M
Non Current Liabilities Total	5.3M	4.8M	3.9M	3.3M	4.4M	2.5M
Inventory	3.6M	3.9M	4.3M	5.4M	12.8M	13.5M
Other Current Assets	407.8K	3.2M	4.3M	885.1K	1.2M	1.1M
Other Stockholder Equity	19.2M	23.7M	25.2M	26.4M	28.2M	18.5M
Total Liab	11.2M	9.7M	10.7M	11.8M	20.7M	21.8M
Property Plant And Equipment Gross	5.0M	4.8M	4.6M	8.0M	15.4M	16.2M
Total Current Assets	59.0M	63.7M	76.2M	78.2M	76.0M	49.0M
Accumulated Other Comprehensive Income	(42.2K)	30.4K	37.1K	17.0K	19.6K	20.5K
Short Term Debt	240.8K	255.7K	276.6K	293.5K	855.9K	528.0K
Intangible Assets	860.1K	960.9K	1.1M	2.1M	2.5M	2.6M
Common Stock	1.2K	1.2K	1.3K	1.3K	1.3K	1.2K
Property Plant Equipment	2.1M	2.1M	4.6M	2.4M	2.8M	1.9M
Net Tangible Assets	54.7M	60.4M	71.1M	71.6M	82.3M	50.6M
Retained Earnings Total Equity	36.3M	37.7M	47.0M	47.3M	54.4M	30.9M
Capital Surpluse	19.2M	23.7M	25.2M	26.4M	30.4M	20.7M
Net Invested Capital	55.5M	61.4M	72.2M	73.7M	71.4M	64.3M
Net Working Capital	53.1M	58.8M	69.4M	69.6M	59.7M	60.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:

How To Invest In Iradimed

Details

Is Iradimed Stock a good investment?

Details

What is Iradimed's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0)

Dividend Share

0.45

Earnings Share

1.46

Revenue Per Share

5.635

Quarterly Revenue Growth

0.11

The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iradimed Total Revenue vs Net Income From Continuing Ops Analysis

Total Revenue vs Net Income From Continuing Ops

Total Revenue vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Total Revenue

Net Income From Continuing Ops

Iradimed fundamental ratios Correlations

Iradimed Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iradimed fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Non Current Assets Total
Retained Earnings	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Current Liabilities
Retained Earnings	+ 0.99	Total Stockholder Equity
Cash	+ 0.99	Total Stockholder Equity

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Retained Earnings	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets
Other Stockholder Equity	- 0.92	Net Debt